Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Phase 2/3 OV company Genelux trades at US$35.00

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jun 20, 2023 3:21pm

179 Views

Post# 35505868

RE:RE:RE:Phase 2/3 OV company Genelux trades at US$35.00

Noteable,

Thanks for pointing out Genelux. I was not aware of that company.

This is a sincere question. Could you provide a quick statement on how that company differs from and/or is similar to ONCY? What do you think their investors see there to maintain their share price, while our share price and market cap is where it is?

Are they ahead of us? Competitors of ours?

In general, share price follows sentifment. That is the simple answer I guess. But I would appreciate the thoughts of any Noteable and any others out there who care to comment.

<< Previous

Bullboard Posts

Next >>

Drilling underway at a large copper-moly porphyry target in Peru